The Global Therapeutic Vaccines Market is estimated at $1132.5 Million in 2015, and is poised to reach $4820.26 Million by 2020 with a CAGR of 33.6%. Currently, in pipeline several approaches are being developed in order to boost the immune response to various infectious and cancerous cells.
The vaccine Market is different from any other product market. Compared to the pharmaceutical market it is relatively small, although growing at a fast rate. There are presently close to 120 new vaccines in the pipeline of various multinational companies across the globe set to hit the market in the next few years. The vaccine market is rather concentrated on both supply and demand sides. It is highly regulated and mostly dependent on public purchasers and donor policies. It has very distinct features which increase the complexity of assessing and understanding pricing and procurement in their context.
Increase in funding’s from government for vaccine development, rise in investments by the major market players, rising prevalence of disease, technological advancements, initiatives by NGO’s are some of the factors that are propelling the market growth. However, massive capital expenditures and stringent regulatory policies, high cost associated with treatment are few factors inhibiting the growth of the market.
The Global Therapeutic Vaccines Market is segmented by the type of disease into Autoimmune Disease Vaccines (Type I Diabetes), Cancer Vaccines (Multikine, PR1 Peptide Vaccine, TroVax, CYT004-MelQbG10 etc.), Neurological Disease Vaccines (ACC-001, CAD106, Parkinson’s Disease Vaccine, Alzheimer's Disease and Other Disease Vaccines), and Infectious Disease Vaccines (Hepatitis C, HIV/AIDS and Other Infectious Disease Vaccines). Furthermore, based on geography the global market is analysed under various regions namely, North America, Europe, Asia Pacific, Latin America and Middle-East & Africa. North America accounts for the large portion of revenue in the therapeutic vaccine market. The growth of this market will be boosted owing to the presence of advanced and active R&D establishments in the region.
Multinational vaccine companies historically have conducted much of the innovation, research, and development in the field of vaccine production. They have used significant revenues, global size, and deeper expertise to fund. Some of the key players influencing the global preventive vaccine market are GlaxoSmithKline, plc., Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Disease Type
5.1.1 Autoimmune Disease Vaccines
5.1.2 Cancer Vaccines
5.1.2.1 Multikine
5.1.2.2 PR1 Peptide
5.1.2.3 TroVax
5.1.2.4 CYT004-MelQbG10
5.1.3 Neurological Disease Vaccines
5.1.3.1 ACC- 001
5.1.3.2 CAD 106
5.1.3.3 Parkinson's Vaccine
5.1.3.4 Alzheimer's Vaccine
5.1.4 Infectious Disease Vaccines
5.1.4.1 Hepatitis C Vaccines
5.1.4.2 HIV/AIDS Vaccines
5.1.4.3 Other Infectious Disease Vaccines
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle East
6.5.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 GlaxoSMithKline plc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Merck and Company
8.3 Bavarian Nordic
8.4 CSL Limited
8.5 Emergent Biosolutions Inc.
8.6 Novartis AG
8.7 Johnson and Johnson
8.8 MedImmune LLC
8.9 Pfizer Inc.
8.10 Sanofi Pasteur
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
